摘要
目的分析在终末期肾病(end-stage renal disease,ESRD)患者维持性血液透析(MHD)治疗中,予以血液透析(HD)+血液透析滤过(HDF)联合干预的效果。方法方便选择2019年1月—2021年10月在丰县人民医院接受MHD治疗的46例ESRD患者为研究对象,依据随机数表法分为对照组(23例,采取单一HD治疗)与观察组(23例,采取HD+HDF联合治疗)。比较两组收缩压(SBP)、舒张压(DBP)、心脏彩超左心室射血分数(EF)、左心室收缩功能(FS)、脑钠肽(BNP)、总蛋白(TP)、血红蛋白(Hb)、C反应蛋白(CRP)水平及不良反应发生率。结果两组患者透析后,观察组SBP、DBP分别为(128.31±7.02)、(76.25±4.21)mmHg,低于对照组的(137.98±9.26)、(82.26±4.86)mmHg,差异有统计学意义(t=3.991、4.483,P<0.05)。观察组EF、FS分别为(59.79±4.40、34.56±4.23)%,高于对照组的(54.87±4.26)%、(30.13±3.14)%,BNP为(112.13±12.25)pg/mL,低于对照组的(176.77±15.31)pg/mL,差异有统计学意义(t=3.853、4.033、15.810,P<0.05)。观察组TP、Hb分别为(74.70±4.35、103.02±6.46)g/L,高于对照组的(69.26±4.88)、(95.46±5.37)g/L,CRP为(6.72±3.48)mg/L,低于对照组的(12.05±3.24)mg/L,差异有统计学意义(t=3.991、4.316、5.376,P<0.05)。观察组不良反应发生率(8.70%)低于对照组(34.78%),差异有统计学意义(χ^(2)=4.600,P<0.05)。结论在ESRD患者MHD治疗中,予以HD+HDF联合治疗效果显著,安全性高。
Objective To analyze the effect of combined hemodialysis(HD)and hemodialytic filtration(HDF)intervention in maintenance hemodialysis(MHD)treatment of patients with end-stage renal disease(ESRD).Methods 46 patients with ESRD who received MHD treatment in the hospital from January 2019 to October 2021 were conveniently selected as the research objects,and were divided into control group(23 patients receiving single HD treatment)and observation group(23 patients receiving HD+HDF combined treatment)according to random number table method.Systolic blood pressure(SBP),diastolic blood pressure(DBP),left ventricular ejection fraction(EF),left ventricular systolic function(FS),brain natriuretic peptide(BNP),total protein(TP),hemoglobin(Hb),C-reactive protein(CRP)and the incidence of adverse reactions were compared between the two groups.Results After dialysis,SBP and DBP in the observation group were respectively(128.31±7.02)mmHg,(76.25±4.21)mmHg,lower than those in the control group(137.98±9.26)mmHg,(82.26±4.86)mmHg,and the difference was statistically significant(t=3.991,4.483,P<0.05).The EF and FS of the observation group were respectively(59.79±4.40)%,34.56±4.23)%,higher than that of the control group(54.87±4.26)%,(30.13±3.14)%,BNP of(112.13±12.25)pg/mL was lower than that of control group(176.77±15.31)pg/mL,and the difference was statistically significant(t=3.853,4.033,15.810,P<0.05).TP and Hb in observation group were respectively(74.70±4.35)g/L,(103.02±6.46)g/L,which were higher than those in control group(69.26±4.88)g/L,(95.46±5.37)g/L,CRP was(6.72±3.48)mg/L,lower than that of control group(12.05±3.24)mg/L,and the difference was statistically significant(t=3.991,4.316,5.376,P<0.05).The incidence of adverse reactions in the observation group(8.70%)was lower than that in the control group(34.78%),and the difference was statistically significant(χ^(2)=4.600,P<0.05).Conclusion In the treatment of MHD in ESRD patients,the combined treatment of HD+HDF has significant effect and high safety.
作者
姜合侠
JIANG Hexia(Department of Nephrology,Fengxian People's Hospital,Fengxian,Jiangsu Province,221700 China)
出处
《中外医疗》
2023年第3期53-56,共4页
China & Foreign Medical Treatment
关键词
血液透析
血液透析滤过
血压
左心室射血分数
左心室收缩功能
脑钠肽
Hemodialysis
Hemodialytic filtration
Blood pressure
Left ventricular ejection fraction
Left ventricular systolic function
Brain natriuretic peptide
